Titan Pharmaceuticals, Inc. (TTNP) Stock Analysis
DELISTED 2025
What happened to Titan Pharmaceuticals, Inc. (TTNP) stock?
Titan Pharmaceuticals, Inc. (TTNP) no longer trades on public markets. It was delisted in October 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Titan Pharmaceuticals, Inc. (TTNP) trades at $2.34. Titan Pharmaceuticals, Inc. focuses on developing therapeutics for chronic diseases using its ProNeura long-term drug delivery platform. Market cap: $3.11M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for TTNP: TTNP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TTNP against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
TTNP: 2/2 scored disciplines lean bearish. Dominant signal: Moon AI bearish.
How is this calculated? →Titan Pharmaceuticals, Inc. (TTNP) Healthcare & Pipeline Overview
Titan Pharmaceuticals, Inc. is a biotechnology company specializing in therapeutics for chronic diseases, utilizing its proprietary ProNeura drug delivery system. Its primary product, Probuphine, addresses opioid use disorder, with ongoing development programs targeting chronic pruritus, opioid relapse prevention, HIV prevention, and contraception.
What Is the Investment Thesis for TTNP?
Titan Pharmaceuticals' investment thesis hinges on the successful expansion of its ProNeura drug delivery platform and the commercialization of its pipeline products. The company's current revenue is primarily derived from Probuphine sales in Canada and the European Union. Key value drivers include the successful development and regulatory approval of TP-2021 for chronic pruritus and the nalmefene implant for opioid relapse prevention. A potential catalyst is the expansion of Probuphine's market share and geographic reach. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from established pharmaceutical companies. The company's small market capitalization and limited resources also pose challenges to its long-term growth prospects. Investors should carefully consider these factors when evaluating Titan Pharmaceuticals' investment potential.
Based on FMP financials and quantitative analysis
TTNP Key Highlights
Probuphine is approved for maintenance treatment of opioid use disorder in Canada and the European Union.
- The company's proprietary ProNeura technology offers long-term drug delivery.
- Titan is developing TP-2021 for chronic pruritus, a condition with significant unmet medical need.
- Nalmefene implant program targets opioid relapse prevention, addressing a critical challenge in addiction treatment.
- The company's small size allows for focused innovation but also presents challenges in resource allocation.
Who Are TTNP's Competitors?
TTNP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNSP CNS Pharmaceuticals, Inc. | $6.00 | +5.26% | $8.77M | 30 |
| ENSC Ensysce Biosciences, Inc. | $0.38 | -3.07% | $5.78M | — |
| KZIA Kazia Therapeutics Limited | $13.67 | -2.84% | $22.1M | 52 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TTNP's Key Strengths?
Proprietary ProNeura drug delivery platform.
- Approved product (Probuphine) for opioid use disorder.
- Pipeline of products targeting unmet medical needs.
- Small size allows for focused innovation.
What Are TTNP's Weaknesses?
Limited financial resources.
- Small market capitalization.
- Dependence on Probuphine sales.
- Limited commercial infrastructure.
What Could Drive TTNP Stock Higher?
Clinical trial results for TP-2021 in chronic pruritus.
- Regulatory approval decisions for nalmefene implant in opioid relapse prevention.
- Expansion of Probuphine market reach in existing and new territories.
- Progress in research and development of HIV preventative therapeutic.
- Development of contraceptive implants for women and adolescent girls.
What Are the Key Risks for TTNP?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for pipeline products.
- Regulatory delays or rejection of product approvals.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on Probuphine sales for revenue.
- Difficulty in securing funding for research and development.
What Are the Growth Opportunities for TTNP?
- Growth opportunity 1: Development and commercialization of TP-2021 for chronic pruritus represents a significant growth opportunity. The chronic pruritus market is underserved, with a growing prevalence due to aging populations and increasing incidence of dermatological conditions. Successful clinical trials and regulatory approval could position TP-2021 as a leading treatment option, capturing a substantial share of the market. The timeline for commercialization depends on clinical trial progress and regulatory review, with potential for market entry within the next 3-5 years.
- Growth opportunity 2: The nalmefene implant program for opioid relapse prevention addresses a critical need in addiction treatment. Opioid relapse rates remain high, highlighting the need for effective long-term prevention strategies. The ProNeura-based nalmefene implant could provide sustained release of the drug, improving patient adherence and reducing relapse risk. Successful development and commercialization could capture a significant portion of the opioid relapse prevention market, estimated to be worth billions of dollars annually. The timeline for market entry is dependent on clinical trial outcomes and regulatory approval.
- Growth opportunity 3: Expanding the market reach of Probuphine beyond Canada and the European Union represents another growth opportunity. The opioid use disorder market is global, with significant unmet needs in many countries. Securing regulatory approvals in new markets, such as the United States and Australia, could significantly increase Probuphine's sales and revenue. This expansion strategy requires navigating complex regulatory pathways and establishing distribution partnerships in new territories. The timeline for market expansion varies depending on the specific country and regulatory requirements.
- Growth opportunity 4: The HIV preventative therapeutic program, utilizing the ProNeura platform, presents a long-term growth opportunity. Developing a long-acting HIV prevention implant could significantly improve adherence and reduce the spread of the virus. This program is in the early stages of development, with significant research and development required before clinical trials can commence. The timeline for potential commercialization is uncertain, but successful development could address a major global health challenge.
- Growth opportunity 5: The contraceptive implant program, also based on the ProNeura platform, offers a potential growth avenue in the women's health market. A single ProNeura implant providing long-term contraception could offer a convenient and effective alternative to existing methods. This program is also in the early stages of development, with significant research and development required. The timeline for potential commercialization is uncertain, but successful development could address a significant unmet need in reproductive health.
What Opportunities Does TTNP Have?
- Expansion of Probuphine market reach.
- Successful development and commercialization of pipeline products.
- Partnerships with larger pharmaceutical companies.
- Licensing of ProNeura technology.
What Are TTNP's Competitive Advantages?
- Proprietary ProNeura drug delivery platform.
- Approved product (Probuphine) in a niche market.
- Pipeline of products targeting unmet medical needs.
- Intellectual property protection for ProNeura technology.
What Does TTNP Do?
Titan Pharmaceuticals, Inc., established in 1992 and based in South San Francisco, California, is a pharmaceutical company dedicated to developing therapeutics for chronic diseases. The company's core technology is ProNeura, a proprietary long-term drug delivery platform designed to provide sustained and consistent drug levels over extended periods. Titan's flagship product, Probuphine, is an implant indicated for the maintenance treatment of opioid use disorder in clinically stable patients. Probuphine is currently available in Canada and the European Union, representing the company's primary revenue stream. Beyond Probuphine, Titan Pharmaceuticals is actively developing a pipeline of products utilizing the ProNeura technology. This includes TP-2021, a kappa opioid agonist peptide program targeting chronic pruritus. Additionally, the company is pursuing a nalmefene implant program aimed at preventing opioid relapse following detoxification. Titan's research and development efforts also encompass programs targeting HIV prevention and contraception, with the goal of creating a single ProNeura implant for women and adolescent girls. These initiatives reflect Titan's commitment to leveraging its ProNeura platform to address a range of unmet medical needs in chronic disease management. The company's small size allows for focused innovation, but also presents challenges in terms of resource allocation and market penetration.
What Products and Services Does TTNP Offer?
- Develop therapeutics for chronic diseases.
- Utilize the ProNeura long-term drug delivery platform.
- Offer Probuphine implant for opioid use disorder maintenance treatment.
- Develop TP-2021 for the treatment of chronic pruritus.
- Develop nalmefene implant for opioid relapse prevention.
- Research HIV preventative therapeutics using ProNeura.
- Research contraceptive implants for women and adolescent girls using ProNeura.
How Does TTNP Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of Probuphine.
- License ProNeura technology to other companies (potential).
- Seek partnerships for product development and commercialization.
What Industry Does TTNP Operate In?
Titan Pharmaceuticals operates within the biotechnology industry, which is characterized by high levels of innovation, regulatory scrutiny, and competition. The market for opioid use disorder treatments is substantial, driven by the ongoing opioid crisis. The chronic pruritus market also represents a significant opportunity, with limited treatment options currently available. Titan's ProNeura technology offers a differentiated approach to drug delivery, potentially providing a competitive advantage. However, the company faces competition from larger pharmaceutical companies with greater resources and established market presence. The biotechnology industry is subject to evolving regulatory landscapes and reimbursement policies, which can impact the commercial success of new therapies.
Who Are TTNP's Key Customers?
- Patients with opioid use disorder.
- Patients with chronic pruritus (future).
- Healthcare providers prescribing Probuphine.
- Pharmacies distributing Probuphine.
Company Profile
Titan Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Petaling Jaya, KY. The company is led by CEO Weei Jye Chay. TTNP has traded publicly since 1996.
Financial Health
Titan Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on assets is -59.1%, showing how much profit it generates from its asset base. A current ratio of 1.40 indicates the company holds enough short-term assets to cover its near-term obligations.
TTNP Valuation & Market Position
With a $3.11M market cap, Titan Pharmaceuticals, Inc. sits in the micro-cap segment of the market.
Forward Outlook
Wall Street analysts project Titan Pharmaceuticals, Inc. revenue of about $35.4M for fiscal 2026, with EPS near $17.40.
TTNP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- There's been chatter about potential partnerships that could really change the game for TTNP. The community seems optimistic about their ability to secure a deal.
- The general feeling is that TTNP is undervalued, with many believing the market hasn't fully recognized its potential.
- Recent insider buying activity has sparked confidence. It suggests those in the know see long-term value.
- A growing number of people are talking about the positive impact Probuphine could have on addressing the opioid crisis, potentially increasing demand.
Bear Case
- The company's history of financial challenges is a recurring concern in discussions. People are worried about their ability to sustain operations.
- There's skepticism about TTNP's ability to effectively compete in the pharmaceutical market, given the presence of larger players.
- Some community members are citing past disappointments with the company's performance as a reason to remain cautious.
- There are worries about potential regulatory hurdles and the time it might take for new products to gain approval.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TTNP Latest News
No recent news available for TTNP.
Leadership: Weei Jye Chay
CEO
Weei Jye Chay serves as the CEO of Titan Pharmaceuticals, Inc. His background includes experience in managing small teams and navigating the complexities of the pharmaceutical industry. He has been instrumental in guiding Titan's strategic direction and overseeing the development of its product pipeline. His leadership is focused on maximizing the potential of the ProNeura technology and expanding the company's market presence. He manages a small team of 4 employees.
Track Record: Under Weei Jye Chay's leadership, Titan Pharmaceuticals has focused on advancing its ProNeura-based product pipeline. Key milestones include continued commercialization of Probuphine in Canada and the European Union, and ongoing development of TP-2021 for chronic pruritus. He has also overseen efforts to secure partnerships and funding to support the company's research and development activities. His focus is on strategic growth and maximizing shareholder value.
TTNP Healthcare Stock FAQ
What happened to Titan Pharmaceuticals, Inc. (TTNP) stock?
Titan Pharmaceuticals, Inc. (TTNP) no longer trades on public markets. It was delisted in October 2025. The figures below are historical and are not a current quote.
Can I still buy TTNP shares?
No. TTNP stopped trading on public markets in October 2025, so the shares are not available through a broker. Anything you see quoted for TTNP elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before TTNP stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Titan Pharmaceuticals, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Titan Pharmaceuticals, Inc. do?
Titan Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes therapeutics for the treatment of chronic diseases, primarily focusing on opioid use disorder and chronic pruritus. The company's core technology is ProNeura, a proprietary long-term drug delivery platform that provides sustained and consistent drug levels over extended periods.
What are the main risks for TTNP?
The main risks for Titan Pharmaceuticals include clinical trial failures, regulatory hurdles, competition from larger pharmaceutical companies, and dependence on Probuphine sales. Clinical trial failures could significantly impact the company's pipeline and future revenue potential. Regulatory delays or rejection of product approvals could also hinder the company's growth prospects.
How does Titan Pharmaceuticals, Inc. navigate regulatory approval processes?
Titan Pharmaceuticals navigates regulatory approval processes by conducting rigorous clinical trials to demonstrate the safety and efficacy of its products. The company works closely with regulatory agencies, such as the FDA and EMA, to ensure compliance with all applicable regulations.
What revenue streams does Titan Pharmaceuticals, Inc. have in healthcare?
Titan Pharmaceuticals' primary revenue stream currently comes from sales of Probuphine in Canada and the European Union. Probuphine is an implant for the maintenance treatment of opioid use disorder. The company anticipates future revenue streams from the commercialization of its pipeline products, including TP-2021 for chronic pruritus and the nalmefene implant for opioid relapse prevention.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for TTNP.
- Financial data based on available information and may be subject to change.
- Forward-looking statements involve risks and uncertainties.